Sana Biotechnology and Mayo Clinic Collaborate to Advance SC451 for Type 1 Diabetes
Tuesday, April 14, 2026
Sana Biotechnology has entered a strategic collaboration with Mayo Clinic to support the development of SC451, an investigational pancreatic islet cell therapy for Type 1 Diabetes.
SC451 is a hypoimmune-modified therapy designed to enable long-term glucose control with a single administration of pancreatic islet cells. The approach aims to remove the need for ongoing insulin treatment and immunosuppression.
The collaboration will use Mayo Clinic’s multidisciplinary expertise to speed up development and standardisation of clinical protocols and processes for SC451. This includes improving workflows, product handling, delivery methods, and post-treatment care to support wider adoption across clinical settings. The partnership will also focus on refining surgical techniques, standardising treatment procedures, and strengthening post-treatment management.
In addition, Mayo Clinic will contribute to clinical trial design, including biomarker identification for patient selection and long-term monitoring. The organisation will also continue to expand its capabilities in delivering investigational islet cell therapies.
As part of the agreement, Mayo Clinic will make an equity investment in Sana Biotechnology, with an option for further investment under agreed terms. The collaboration reflects a shared aim to advance innovative treatment approaches and improve care for patients with type 1 diabetes.
Source: sana.com
